(Total Views: 326)
Posted On: 11/26/2018 6:04:38 PM
Post# of 721
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Submits Health Canada Research Application, Appoints Chief Legal Officer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced its submittal of a Health Canada research application, as well as the appointment of Dr. Ed Ergenzinger to its executive team. The company’s research application, submitted under Health Canada’s Cannabis Tracking and Licensing System, is for the operation of an R&D laboratory to work with cannabinoids within Lexaria’s under construction Kelowna-based head office. According to the update, the laboratory will enhance Lexaria’s ability to formulate various products, which may contain cannabinoids or other controlled substances, for analytical purposes. In addition, the company appointed Dr. Ed Ergenzinger to the positions of chief legal officer and senior vice president of innovation. Ergenzinger is a U.S.-licensed patent attorney holding a doctorate in neuroscience (with concentrations in pharmacology and physiology) and an adjunct professor of law. He has over 15 years of experience providing patent services for clients ranging from small to some of the world’s largest pharmaceutical and biotechnology companies.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced its submittal of a Health Canada research application, as well as the appointment of Dr. Ed Ergenzinger to its executive team. The company’s research application, submitted under Health Canada’s Cannabis Tracking and Licensing System, is for the operation of an R&D laboratory to work with cannabinoids within Lexaria’s under construction Kelowna-based head office. According to the update, the laboratory will enhance Lexaria’s ability to formulate various products, which may contain cannabinoids or other controlled substances, for analytical purposes. In addition, the company appointed Dr. Ed Ergenzinger to the positions of chief legal officer and senior vice president of innovation. Ergenzinger is a U.S.-licensed patent attorney holding a doctorate in neuroscience (with concentrations in pharmacology and physiology) and an adjunct professor of law. He has over 15 years of experience providing patent services for clients ranging from small to some of the world’s largest pharmaceutical and biotechnology companies.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Scroll down for more posts ▼
